These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22702491)

  • 1. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.
    Carradori S; Secci D; Bolasco A; Chimenti P; D'Ascenzio M
    Expert Opin Ther Pat; 2012 Jul; 22(7):759-801. PubMed ID: 22702491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on new monoamine oxidase inhibitors.
    Bolasco A; Carradori S; Fioravanti R
    Expert Opin Ther Pat; 2010 Jul; 20(7):909-39. PubMed ID: 20553094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAO inhibitors and their wider applications: a patent review.
    Carradori S; Secci D; Petzer JP
    Expert Opin Ther Pat; 2018 Mar; 28(3):211-226. PubMed ID: 29324067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs related to monoamine oxidase activity.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).
    Carradori S; Petzer JP
    Expert Opin Ther Pat; 2015 Jan; 25(1):91-110. PubMed ID: 25399762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
    Gaspar A; Reis J; Fonseca A; Milhazes N; Viña D; Uriarte E; Borges F
    Bioorg Med Chem Lett; 2011 Jan; 21(2):707-9. PubMed ID: 21194943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated patent review on monoamine oxidase (MAO) inhibitors.
    Guglielmi P; Carradori S; D'Agostino I; Campestre C; Petzer JP
    Expert Opin Ther Pat; 2022 Aug; 32(8):849-883. PubMed ID: 35638744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase.
    Strydom B; Bergh JJ; Petzer JP
    Eur J Med Chem; 2011 Aug; 46(8):3474-85. PubMed ID: 21621312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6632-5. PubMed ID: 23010267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
    Naoi M; Maruyama W; Inaba-Hasegawa K; Akao Y
    Int Rev Neurobiol; 2011; 100():85-106. PubMed ID: 21971004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents.
    Secci D; Bolasco A; Chimenti P; Carradori S
    Curr Med Chem; 2011; 18(33):5114-44. PubMed ID: 22050759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of monoamine oxidase inhibitors in chronic neurodegeneration.
    Riederer P; Müller T
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):233-240. PubMed ID: 27998194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.
    Herraiz T; Chaparro C
    Biochem Biophys Res Commun; 2005 Jan; 326(2):378-86. PubMed ID: 15582589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
    Youdim MB; Bakhle YS
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.